These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 4090353)

  • 1. [Structural-functional state of the genetic apparatus of blood leukocytes in breast cancer patients during cytostatic therapy].
    Ishkhanova MA; Mitriaeva NA; Gaĭseniuk LA
    Vopr Med Khim; 1985; 31(5):110-2. PubMed ID: 4090353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in the content of CD34+ cells in the peripheral blood of cancer patients receiving out-patient chemotherapy.
    Waller EK; Barlett N; Chen CH; Mujic V; Sussman H; Toepker S; Grenier K
    Cytotherapy; 1999; 1(1):21-9. PubMed ID: 19746646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognosis for therapeutic effectiveness of radiotherapy in the combined treatment of cancer].
    Ivanov SD
    Vopr Onkol; 2008; 54(4):483-9. PubMed ID: 18942405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Increased apoptosis of peripheral blood leukocytes correlates with leukopenia after high-dose chemotherapy].
    Chukhlovin AB
    Vopr Onkol; 1999; 45(4):384-6. PubMed ID: 10532096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of toxicities induced by chemotherapy in breast cancer patients.
    Mehreen L; Khanam A
    Biomed Pharmacother; 2005 Oct; 59(9):524-7. PubMed ID: 16154313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The leucocyte nadir, a predictor of chemotherapy efficacy?
    Kvinnsland S
    Br J Cancer; 1999 Aug; 80(11):1681. PubMed ID: 10468282
    [No Abstract]   [Full Text] [Related]  

  • 7. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular DNA in breast cancer: Cell-surface-bound, tumor-derived extracellular DNA in blood of patients with breast cancer and nonmalignant tumors.
    Rykova EY; Laktionov PP; Skvortsova TE; Starikov AV; Kuznetsova NP; Vlassov VV
    Ann N Y Acad Sci; 2004 Jun; 1022():217-20. PubMed ID: 15251963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic NF-kappaB activation in blood cells of breast cancer patients.
    Adzić M; Nićiforović A; Vucić V; Nesković-Konstantinović Z; Spasić SD; Jones DR; Radojcić MB; Spasić MB
    Redox Rep; 2006; 11(1):39-44. PubMed ID: 16571274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer.
    Sánchez-Suárez P; Ostrosky-Wegman P; Gallegos-Hernández F; Peñarroja-Flores R; Toledo-García J; Bravo JL; Del Castillo ER; Benítez-Bribiesca L
    Mutat Res; 2008 Apr; 640(1-2):8-15. PubMed ID: 18207203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells.
    Weaver CH; Moss T; Schwartzberg LS; Zhen B; West J; Rhinehart S; Campos L; Beeker T; Lautersztain L; Messino M; Buckner CD
    Bone Marrow Transplant; 1998 Jun; 21(11):1117-24. PubMed ID: 9645574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive cyclic chemotherapy with unprocessed whole blood support in advanced breast cancer.
    Vanásek J; Filip S; Medková V; Bláha M; Maricka P; Stránský P; Vavrová J
    Neoplasma; 2001; 48(1):34-8. PubMed ID: 11327535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity and tolerability of a combined palliative chemotherapy with mitomycin C, folinate, and 5-Fluorouracil in patients with advanced breast cancer after intensive pretreatment: a retrospective analysis.
    Eichbaum MH; Gast AS; Schneeweiss A; Bruckner T; Sohn C
    Am J Clin Oncol; 2007 Apr; 30(2):139-45. PubMed ID: 17414462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early intensive and myeloablative adjuvant chemotherapy in women with high-risk breast cancer.
    Wörmann B; Meden H; Riggert J; Humpe A; Wulf G; Koch B; Köhler M; Kuhn W; Hiddemann W
    Anticancer Res; 1998; 18(3C):2237-41. PubMed ID: 9703793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.
    Poikonen P; Saarto T; Lundin J; Joensuu H; Blomqvist C
    Br J Cancer; 1999 Aug; 80(11):1763-6. PubMed ID: 10468293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
    Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
    Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral progenitor cells (PBPC) in supportive care after high-dose chemotherapy in breast cancer.
    Filip S; Bláha M; Petera J; Vavrová J; Knízek J
    Neoplasma; 2001; 48(1):39-47. PubMed ID: 11327536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Primary chemotherapy in breast cancer. Preliminary results].
    Jacquillat C; Auclerc G; Baillet F; Blondon J; Maral J; Strich-Mougenot C; Lefranc JP; Maylin C; Weil M
    Ann Med Interne (Paris); 1984; 135(4):291-5. PubMed ID: 6476666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.